Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Cisco who wrote (1398)	2/6/1998 11:12:00 AM
From: Frank Buck	Respond to of 1894

Cisco, Digene has announced a presence in the U.K. As you are probably aware that is an area where present HPV testing methodology and detection is considered weak in comparison to other industrialized countries. Digene has found a U.K. clinical lab to pilot Digene's Hybrid Capture HPV DNA test. biz.yahoo.com <Digene Corporation develops, manufactures and markets DNA and RNA tests for the detection, screening and monitoring of human diseases. Digene's products are designed to help improve clinical outcomes and reduce the overall cost of disease management. Digene's lead product, the Hybrid Capture HPV DNA test, aids physicians in identifying women who are most at risk of having or developing cervical disease and cervical cancer. Digene's HPV test is used in the U.S as an adjunct to the Pap smear for cervical cancer screening and is being evaluated in selected European and South American countries as a primary cervical cancer screen either in conjunction with or separate from the Pap smear. Et tu Brutti ! Frank